null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.94x Total Debt / Equity (Moderate leverage)

Moderate sensitivity; ~$700M long-term debt at mostly fixed rates, 20bp rise adds ~$1.4M annual interest cost, manageable given $400M+ operating cash flow

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Malaysian semiconductor/MEMS fabrication concentration and Chinese electronics component manufacturing represent top two geopolitical chokepoints

EUR (~35% intl revenue), GBP (~10%), and CAD (~5%) exposure; EUR/USD volatility historically creates 2-4% revenue headwind in strong-dollar years

Primary markets EU, UK, Canada face moderate devaluation risk; EUR weakness vs USD in 2022 created ~$50M revenue headwind; hedging program partially offsets

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Flextronics/Flex Ltd. manufactures OmniPod hardware; single critical contract manufacturer representing high operational dependency, difficult to substitute quickly

Medical device hardware/SaaS hybrid; cloud disruption would impair Omnipod 5 algorithm delivery and connectivity but not basic insulin delivery function

Consumable pod subscription model; 30-day cloud termination would disrupt automated insulin delivery features but manual mode preserves core functionality

Dexcom CGM API integration for Omnipod 5 creates meaningful coupling risk; FDA re-approval required for alternative CGM integrations, creating 12-24 month switching delay

Near-zero Howey Test risk; revenue from FDA-regulated medical device sales and pod subscriptions, no investment contract or profit-sharing scheme present

Very High

Moderate GDPR exposure with EU patient glucose data; CCPA applies to California users; ISO 27001 certified, but cross-border health data transfers carry ongoing regulatory scrutiny

Low-moderate; competes with Medtronic, Tandem in insulin pump market; no dominant monopoly position, though exclusive CGM partnerships could draw scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~85% recurring via consumable pod replenishment (every 3 days replacement cycle); ~15% transactional PDM/controller hardware sales

Consumable razor-and-blade model; PDM controller subsidized or low-margin, high-margin recurring pod sales drive economics at ~$300-400 annual pod spend per patient

Reimbursement-dependent pricing; Medicare/Medicaid rate cuts or formulary exclusions would directly compress ASPs; limited direct pricing power without payer negotiation leverage

6/10; strong clinical differentiation and tubeless advantage provide moderate pricing power, but payer reimbursement caps and formulary dynamics constrain unilateral price increases

71.6% Gross Margin (Premium (>60%))

Very low free-rider risk; pods are physical consumables requiring purchase, no digital free tier exists; churn driven primarily by competitor switching or clinical failure

Sublinear; manufacturing scale and automation reduce per-unit labor cost, but R&D and regulatory headcount grows with product pipeline; estimated 0.6x headcount ratio at 2x revenue

Moderately capital-intensive but improving; incremental pod manufacturing costs declining with scale; gross margin expanding from ~64% toward ~68-70% target at scale

null

At 10x scale, CAC likely compresses via physician network effects and referral density; current ~$500-700 CAC per patient could fall 30-40% with brand saturation in diabetes community

Weak direct network effects; stronger indirect effects via physician familiarity, CDE training ecosystem, and CGM interoperability partnerships reinforcing platform stickiness

10.6% Return on Assets (Excellent)

Tier 1 recession resistant; insulin delivery is non-discretionary for Type 1 diabetics; reimbursement coverage insulates demand, though Type 2 adoption is more discretionary

Type 1 diabetes patients (~80% of revenue base); highly concentrated medically necessary use case with strong retention and lifetime value exceeding $10,000

Insulin-dependent Type 2 diabetes patients (~20% growing segment); more price-sensitive, less clinically urgent, representing expansion opportunity but higher churn risk

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

7.1% CapEx / Revenue (Moderate-CapEx)

0001145197

PODD